Diamond Equity Lowers Earnings Estimates for ProPhase Labs

ProPhase Labs, Inc. (NASDAQ:PRPH) – Equities researchers at Diamond Equity lowered their FY2024 earnings per share estimates for shares of ProPhase Labs in a research report issued on Thursday, February 13th. Diamond Equity analyst H. Diamond now expects that the company will post earnings per share of ($1.27) for the year, down from their previous estimate of ($1.23). The consensus estimate for ProPhase Labs’ current full-year earnings is ($1.23) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.56) EPS.

Separately, StockNews.com started coverage on ProPhase Labs in a report on Monday. They issued a “sell” rating on the stock.

ProPhase Labs Price Performance

Shares of PRPH opened at $0.33 on Monday. The firm has a market cap of $7.76 million, a price-to-earnings ratio of -0.26 and a beta of -0.37. The stock has a 50 day moving average of $0.55 and a 200-day moving average of $1.51. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48. ProPhase Labs has a 52 week low of $0.22 and a 52 week high of $7.48.

Institutional Trading of ProPhase Labs

Several hedge funds have recently added to or reduced their stakes in PRPH. SVB Wealth LLC acquired a new position in shares of ProPhase Labs in the 4th quarter worth $36,000. Squarepoint Ops LLC purchased a new position in shares of ProPhase Labs during the fourth quarter valued at $40,000. Warberg Asset Management LLC purchased a new position in shares of ProPhase Labs during the fourth quarter valued at $77,000. Perritt Capital Management Inc grew its holdings in shares of ProPhase Labs by 129.1% during the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after buying an additional 107,068 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of ProPhase Labs by 26.6% during the fourth quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock valued at $154,000 after buying an additional 42,793 shares in the last quarter. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.